Global G-Protein Coupled Receptors (GPCRs) Industry

NEW YORK, Nov. 19, 2020 /PRNewswire/ --

Read the full report: https://www.reportlinker.com/p05817993/?utm_source=PRN

The global market for G-Protein Coupled Receptors (GPCRs) is projected to reach US$3.8 billion by the year 2027, trailing a post COVID-19 CAGR of 5.7% over the analysis period 2020 through 2027. Global healthcare systems continue to be inadequate, leaving a lot to be desired. Over 50% of the world’s population lacks access to essential health services. Low quality healthcare is increasing the burden of disease, morality in addition to pushing up medical costs. COVID-19 is bringing transformational change in the way the world is beginning to prioritize healthcare and drug development. Post pandemic, there will be robust need and demand for the development of new and affordable medicines. The scenario brings good news for G-Protein Coupled Receptors (GPCRs), given the fact that over 45% of all drugs work by targeting GPCRs. The most intensively studied class of drug targets, GPCRs represent signal-transducing molecules that transmit signals to cells. They play a key role in converting extracellular stimulus into intracellular responses, and are therefore responsible for all physiological processes. Also referred to as heptahelical receptor or seven-trans membrane receptor, GPCRs consist of a large family of trans-membrane receptor proteins that play a vital role in signal transduction pathways in various physiological processes. Thus, by targeting GPCRs, a number of cellular functions can be controlled. GPCR-based drugs represent around 40% of the total approved drugs available in the market.

In addition, GPCRs that were previously untargeted are fast becoming validated targets, with an average of 3.5 receptors each year. G protein-coupled receptors (GPCRs) are membrane proteins that are located on the surface of a cell. Human genome comprises of around 30,000 genes, of which around 10% (3,000) genes are found to be drug gable targets. Out of the 3,000 genes, GPCRs are encoded by approximately 800-1,000 genes in the human body, and thus, comprise of the largest cell-surface receptor family. Furthermore, in the GPCR superfamily only around 360 receptors are non-chemosensory/ non-sensory and thus, are identified as validated drug targets, while the remaining are sensory receptors. GPCRs are present only in eukaryotes such as choanoflagellates and yeast, as well as in animals. GPCRs are also called 7TM receptors, 7trans-membrane domain receptors, serpentine receptors, and G-protein linked receptors (GPLR), and heptahelical receptors. The transmembrane domains are linked by 3 extracellular and 3 intracellular loops. The most important feature of GPCRs is that they are expressed at the surface of the cell, and communicate certain specific aspects of the extra-cellular environment to the intra-cellular environment.

Drugs targeting GPCR have superior therapeutic benefits, as they are more active at cell surface receptors. The importance of GPCRs can be put into perspective by the fact that approximately 35% to 40% of all pharmaceutical drugs in the marketplace target G-protein coupled receptors, making it one of the most vital classes of proteins in the genome. G protein?coupled receptors (GPCRs) are important drug targets with about 35% of FDA approved drugs targeting these receptors. GPCRs stimulate cellular responses and signal transduction inside the cell, upon sensing molecules outside. GPCR respond to various agonists, including proteins, neurotransmitters, hormones, amines, and photon. Some of the agonists attach themselves to receptors extra cellular loop, while others penetrate in the trans-membrane region. Upon activation, a conformational change is induced in the receptor, which in turn activates GPCRs and subsequently biochemical signals are transmitted in the cell. Over the past two decades, there has been much research on understanding working of the receptors at the molecular level. There are also many studies ongoing for developing structure based GPCR drug designing, based on discoveries that various ligands are able to bind to same receptor but stimulate association of other effector proteins to varying extents. Such concept of biased agonism as well as functional selectivity have opened up major possibilities for development of more effective drugs with more desired therapeutic impacts, all while preventing harmful side-effects. Already, there have been many illustrations of how such biased GPCR ligands could prove to be useful in treating various diseases. Nonetheless, there is still much to be learnt about the various mechanisms that govern functional selectivity and ligand bias. Growth is forecast to be primarily driven by the increasing interest in GPCR drug targets, superior understanding of GPCR membrane structures, identification, and crystallization of newer structures, development of more powerful and efficient GPCR screening tools and technologies, and successful extrapolation of known structural information to other GPCRs of therapeutic interest. More than 360 endoGPCRs represent the largest and most therapeutically targeted class of membrane receptors in humans. However only 30-40% that have well-defined biological ligands are drug gable at present. The remaining 60-70% hold significant potential for development of new drug therapeutics.

Competitors identified in this market include, among others,

• Abcam PLC
• BD Biosciences
• Cisbio Bioassays
• DiscoveRx Corporation
• Enzo Life Sciences, Inc.
• HD Biosciences (China) Co., Ltd.
• MilliporeSigma
• MilliporeSigma
• PerkinElmer, Inc.
• Promega Corporation
• QIAGEN NV
• Thermo Fisher Scientific, Inc.

Read the full report: https://www.reportlinker.com/p05817993/?utm_source=PRN

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE I-1

II. EXECUTIVE SUMMARY II-1

1. MARKET OVERVIEW II-1
Impact of Covid-19 and a Looming Global Recession II-1
GPCR: An Introduction II-2
Important Role of GPCRs in Drug Discovery II-3
Popular Types of GPCRs of Therapeutic Interest II-4
Classification of GPCRs II-5
Orphan GPCRs: A Promising Area for Drug Discovery II-5
GPCR Signaling Pathways II-6
Physiological Roles Performed by GPCRs II-6
Outlook II-7
Geographic Market Analysis II-8
Challenges II-9
Competition II-9
Recent Market Activity II-10
World Brands II-11

2. FOCUS ON SELECT PLAYERS II-12

3. MARKET TRENDS & DRIVERS II-13
Therapeutic Potential of GPCRs Gains Wide Recognition II-13
Allosteric Modulators and Implication of Allostery in Drug
Discovery II-14
GPCRs Registered as Targets for Approved Drugs with EMBL-
CHEMBL, IUPHAR, and The DrugBank II-15
GPCRs Registered as Targets for Approved Drugs with EMBL-CHEMBL II-15
GPCRs Registered as Targets for Approved Drugs with
International Union of Basic and Clinical Pharmacology (
IUPHAR) II-16
GPCRs Registered as Targets for Approved Drugs with The DrugBank II-17
FDA Approved GPCR Targeting Drugs (Excl. Diagnostic Agents) for
the Period 2015-2019 II-18
Hurdles Faced II-20
Developments in Structural Biology and Receptor Pharmacology
Offer Novel Opportunities to GPCR Drug Discovery II-21
In Silico Approaches Underway for GPCR Drug Screening II-21
Microfluidic Cell Technology Holds Potential II-22
Pipeline GPCR Drug Candidates Widen Prospects II-23
Select GPCR Small Molecule Drugs in Active Clinical Development II-23
GPCR Ligands (Agonist) in Phase III Clinical Development II-25
GPCR Ligands (Antagonist) in Phase III Clinical Development II-27
ION CHANNELS and GPCRs II-28
New Indications to Aid Growth II-28
CRISPR Holds Potential to Speed Up GPCR-based Drug Discovery II-28
GPCR-targeted Drugs and Role in Cancer Treatment II-30
Select FDA Approved Drugs and Antibodies against Various Cancer
Types II-31
Potential GPCR targets for Cancer Treatment II-31
Anti GPCRs Drugs and Antibodies by Clinical Trial Phase II-32
Rising Incidence of Cancer to Drive Drives Opportunities II-33
Exhibit 1: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 II-33
Exhibit 2: Global Number of New Cancer Cases and Cancer-related
Deaths by Cancer Site for 2018 II-34
GPCRs Evolve as Important Targets for Developing Novel
Therapeutics for Neurodegerative Disorders II-35
Exhibit 3: Number of Individuals Suffering from Alzheimer’s in
the US: 2020 and 2025 II-36
Exhibit 4: Global Aging Population Statistics for the 65+ Age
Group in Million by Geographic Region for the Years 2019,
2025, 2035 and 2050 II-36
GPCRs: An Important Target for Cardiovascular Drugs II-37
Exhibit 5: Fatalities by Heart Conditions - Estimated
Percentage Breakdown for Cardiovascular Disease, Ischemic
Heart Disease, Stroke, and Others II-38
GPCR Screening and Targeting Technologies II-38

4. GLOBAL MARKET PERSPECTIVE II-41
Table 1: World Current & Future Analysis for G-Protein Coupled
Receptors (GPCRs) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-41

Table 2: World Historic Review for G-Protein Coupled Receptors
(GPCRs) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 II-42

Table 3: World 12-Year Perspective for G-Protein Coupled
Receptors (GPCRs) by Geographic Region - Percentage Breakdown
of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets for Years 2015, 2020 &
2027 II-43

Table 4: World Current & Future Analysis for Cell Lines by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 II-44

Table 5: World Historic Review for Cell Lines by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2015 through 2019 II-45

Table 6: World 12-Year Perspective for Cell Lines by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2015, 2020 & 2027 II-46

Table 7: World Current & Future Analysis for Detection Kits by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 II-47

Table 8: World Historic Review for Detection Kits by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2015 through 2019 II-48

Table 9: World 12-Year Perspective for Detection Kits by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2020 & 2027 II-49

Table 10: World Current & Future Analysis for Cell Culture
Reagents by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 II-50

Table 11: World Historic Review for Cell Culture Reagents by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2015 through 2019 II-51

Table 12: World 12-Year Perspective for Cell Culture Reagents
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2020 & 2027 II-52

Table 13: World Current & Future Analysis for Ligands by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 II-53

Table 14: World Historic Review for Ligands by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2015 through 2019 II-54

Table 15: World 12-Year Perspective for Ligands by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2015, 2020 & 2027 II-55

Table 16: World Current & Future Analysis for cAMP Functional
Assays by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 II-56

Table 17: World Historic Review for cAMP Functional Assays by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2015 through 2019 II-57

Table 18: World 12-Year Perspective for cAMP Functional Assays
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2020 & 2027 II-58

Table 19: World Current & Future Analysis for Calcium
Functional Assays by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-59

Table 20: World Historic Review for Calcium Functional Assays
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2015 through 2019 II-60

Table 21: World 12-Year Perspective for Calcium Functional
Assays by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2015, 2020 & 2027 II-61

Table 22: World Current & Future Analysis for •-Arrestin
Functional Assays by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-62

Table 23: World Historic Review for •-Arrestin Functional
Assays by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 II-63

Table 24: World 12-Year Perspective for •-Arrestin Functional
Assays by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2015, 2020 & 2027 II-64

Table 25: World Current & Future Analysis for Radioligand
Binding & GTPyS Functional Assays by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 II-65

Table 26: World Historic Review for Radioligand Binding & GTPyS
Functional Assays by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 II-66

Table 27: World 12-Year Perspective for Radioligand Binding &
GTPyS Functional Assays by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2015, 2020 & 2027 II-67

Table 28: World Current & Future Analysis for Internalization
Assays by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 II-68

Table 29: World Historic Review for Internalization Assays by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2015 through 2019 II-69

Table 30: World 12-Year Perspective for Internalization Assays
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2020 & 2027 II-70

Table 31: World Current & Future Analysis for Other Assay Types
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 II-71

Table 32: World Historic Review for Other Assay Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2015 through 2019 II-72

Table 33: World 12-Year Perspective for Other Assay Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2020 & 2027 II-73

Table 34: World Current & Future Analysis for Cancer Research
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 II-74

Table 35: World Historic Review for Cancer Research by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2015 through 2019 II-75

Table 36: World 12-Year Perspective for Cancer Research by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2020 & 2027 II-76

Table 37: World Current & Future Analysis for Metabolic
Research by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 II-77

Table 38: World Historic Review for Metabolic Research by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2015 through 2019 II-78

Table 39: World 12-Year Perspective for Metabolic Research by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2020 & 2027 II-79

Table 40: World Current & Future Analysis for Inflammation
Research by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 II-80

Table 41: World Historic Review for Inflammation Research by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2015 through 2019 II-81

Table 42: World 12-Year Perspective for Inflammation Research
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2020 & 2027 II-82

Table 43: World Current & Future Analysis for CNS Research by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 II-83

Table 44: World Historic Review for CNS Research by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2015 through 2019 II-84

Table 45: World 12-Year Perspective for CNS Research by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2020 & 2027 II-85

Table 46: World Current & Future Analysis for Respiratory
Research by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 II-86

Table 47: World Historic Review for Respiratory Research by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2015 through 2019 II-87

Table 48: World 12-Year Perspective for Respiratory Research by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2020 & 2027 II-88

Table 49: World Current & Future Analysis for Cardiovascular
Research by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 II-89

Table 50: World Historic Review for Cardiovascular Research by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2015 through 2019 II-90

Table 51: World 12-Year Perspective for Cardiovascular Research
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2020 & 2027 II-91

Table 52: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 II-92

Table 53: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2015 through 2019 II-93

Table 54: World 12-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2020 & 2027 II-94

III. MARKET ANALYSIS III-1

GEOGRAPHIC MARKET ANALYSIS III-1

UNITED STATES III-1
Table 55: USA Current & Future Analysis for G-Protein Coupled
Receptors (GPCRs) by Product - Cell Lines, Detection Kits, Cell
Culture Reagents and Ligands - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 III-1

Table 56: USA Historic Review for G-Protein Coupled Receptors
(GPCRs) by Product - Cell Lines, Detection Kits, Cell Culture
Reagents and Ligands Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2015 through 2019 III-2

Table 57: USA 12-Year Perspective for G-Protein Coupled
Receptors (GPCRs) by Product - Percentage Breakdown of Value
Sales for Cell Lines, Detection Kits, Cell Culture Reagents and
Ligands for the Years 2015, 2020 & 2027 III-3

Table 58: USA Current & Future Analysis for G-Protein Coupled
Receptors (GPCRs) by Assay Type - cAMP Functional Assays,
Calcium Functional Assays, •-Arrestin Functional Assays,
Radioligand Binding & GTPyS Functional Assays, Internalization
Assays and Other Assay Types - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 III-4

Table 59: USA Historic Review for G-Protein Coupled Receptors
(GPCRs) by Assay Type - cAMP Functional Assays, Calcium
Functional Assays, •-Arrestin Functional Assays, Radioligand
Binding & GTPyS Functional Assays, Internalization Assays and
Other Assay Types Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2015 through 2019 III-5

Table 60: USA 12-Year Perspective for G-Protein Coupled
Receptors (GPCRs) by Assay Type - Percentage Breakdown of Value
Sales for cAMP Functional Assays, Calcium Functional Assays,
•-Arrestin Functional Assays, Radioligand Binding & GTPyS
Functional Assays, Internalization Assays and Other Assay Types
for the Years 2015, 2020 & 2027 III-6

Table 61: USA Current & Future Analysis for G-Protein Coupled
Receptors (GPCRs) by Application - Cancer Research, Metabolic
Research, Inflammation Research, CNS Research, Respiratory
Research, Cardiovascular Research and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-7

Table 62: USA Historic Review for G-Protein Coupled Receptors
(GPCRs) by Application - Cancer Research, Metabolic Research,
Inflammation Research, CNS Research, Respiratory Research,
Cardiovascular Research and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 III-8

Table 63: USA 12-Year Perspective for G-Protein Coupled
Receptors (GPCRs) by Application - Percentage Breakdown of
Value Sales for Cancer Research, Metabolic Research,
Inflammation Research, CNS Research, Respiratory Research,
Cardiovascular Research and Other Applications for the Years
2015, 2020 & 2027 III-9

CANADA III-10
Table 64: Canada Current & Future Analysis for G-Protein
Coupled Receptors (GPCRs) by Product - Cell Lines, Detection
Kits, Cell Culture Reagents and Ligands - Independent Analysis
of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-10

Table 65: Canada Historic Review for G-Protein Coupled
Receptors (GPCRs) by Product - Cell Lines, Detection Kits, Cell
Culture Reagents and Ligands Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2015 through 2019 III-11

Table 66: Canada 12-Year Perspective for G-Protein Coupled
Receptors (GPCRs) by Product - Percentage Breakdown of Value
Sales for Cell Lines, Detection Kits, Cell Culture Reagents and
Ligands for the Years 2015, 2020 & 2027 III-12

Table 67: Canada Current & Future Analysis for G-Protein
Coupled Receptors (GPCRs) by Assay Type - cAMP Functional
Assays, Calcium Functional Assays, •-Arrestin Functional
Assays, Radioligand Binding & GTPyS Functional Assays,
Internalization Assays and Other Assay Types - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 III-13

Table 68: Canada Historic Review for G-Protein Coupled
Receptors (GPCRs) by Assay Type - cAMP Functional Assays,
Calcium Functional Assays, •-Arrestin Functional Assays,
Radioligand Binding & GTPyS Functional Assays, Internalization
Assays and Other Assay Types Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2015 through 2019 III-14

Table 69: Canada 12-Year Perspective for G-Protein Coupled
Receptors (GPCRs) by Assay Type - Percentage Breakdown of Value
Sales for cAMP Functional Assays, Calcium Functional Assays,
•-Arrestin Functional Assays, Radioligand Binding & GTPyS
Functional Assays, Internalization Assays and Other Assay Types
for the Years 2015, 2020 & 2027 III-15

Table 70: Canada Current & Future Analysis for G-Protein
Coupled Receptors (GPCRs) by Application - Cancer Research,
Metabolic Research, Inflammation Research, CNS Research,
Respiratory Research, Cardiovascular Research and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 III-16

Table 71: Canada Historic Review for G-Protein Coupled
Receptors (GPCRs) by Application - Cancer Research, Metabolic
Research, Inflammation Research, CNS Research, Respiratory
Research, Cardiovascular Research and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2015 through 2019 III-17

Table 72: Canada 12-Year Perspective for G-Protein Coupled
Receptors (GPCRs) by Application - Percentage Breakdown of
Value Sales for Cancer Research, Metabolic Research,
Inflammation Research, CNS Research, Respiratory Research,
Cardiovascular Research and Other Applications for the Years
2015, 2020 & 2027 III-18

JAPAN III-19
Table 73: Japan Current & Future Analysis for G-Protein Coupled
Receptors (GPCRs) by Product - Cell Lines, Detection Kits, Cell
Culture Reagents and Ligands - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 III-19

Table 74: Japan Historic Review for G-Protein Coupled Receptors
(GPCRs) by Product - Cell Lines, Detection Kits, Cell Culture
Reagents and Ligands Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2015 through 2019 III-20

Table 75: Japan 12-Year Perspective for G-Protein Coupled
Receptors (GPCRs) by Product - Percentage Breakdown of Value
Sales for Cell Lines, Detection Kits, Cell Culture Reagents and
Ligands for the Years 2015, 2020 & 2027 III-21

Table 76: Japan Current & Future Analysis for G-Protein Coupled
Receptors (GPCRs) by Assay Type - cAMP Functional Assays,
Calcium Functional Assays, •-Arrestin Functional Assays,
Radioligand Binding & GTPyS Functional Assays, Internalization
Assays and Other Assay Types - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 III-22

Table 77: Japan Historic Review for G-Protein Coupled Receptors
(GPCRs) by Assay Type - cAMP Functional Assays, Calcium
Functional Assays, •-Arrestin Functional Assays, Radioligand
Binding & GTPyS Functional Assays, Internalization Assays and
Other Assay Types Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2015 through 2019 III-23

Table 78: Japan 12-Year Perspective for G-Protein Coupled
Receptors (GPCRs) by Assay Type - Percentage Breakdown of Value
Sales for cAMP Functional Assays, Calcium Functional Assays,
•-Arrestin Functional Assays, Radioligand Binding & GTPyS
Functional Assays, Internalization Assays and Other Assay Types
for the Years 2015, 2020 & 2027 III-24

Table 79: Japan Current & Future Analysis for G-Protein Coupled
Receptors (GPCRs) by Application - Cancer Research, Metabolic
Research, Inflammation Research, CNS Research, Respiratory
Research, Cardiovascular Research and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-25

Table 80: Japan Historic Review for G-Protein Coupled Receptors
(GPCRs) by Application - Cancer Research, Metabolic Research,
Inflammation Research, CNS Research, Respiratory Research,
Cardiovascular Research and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 III-26

Table 81: Japan 12-Year Perspective for G-Protein Coupled
Receptors (GPCRs) by Application - Percentage Breakdown of
Value Sales for Cancer Research, Metabolic Research,
Inflammation Research, CNS Research, Respiratory Research,
Cardiovascular Research and Other Applications for the Years
2015, 2020 & 2027 III-27

CHINA III-28
Table 82: China Current & Future Analysis for G-Protein Coupled
Receptors (GPCRs) by Product - Cell Lines, Detection Kits, Cell
Culture Reagents and Ligands - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 III-28

Table 83: China Historic Review for G-Protein Coupled Receptors
(GPCRs) by Product - Cell Lines, Detection Kits, Cell Culture
Reagents and Ligands Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2015 through 2019 III-29

Table 84: China 12-Year Perspective for G-Protein Coupled
Receptors (GPCRs) by Product - Percentage Breakdown of Value
Sales for Cell Lines, Detection Kits, Cell Culture Reagents and
Ligands for the Years 2015, 2020 & 2027 III-30

Table 85: China Current & Future Analysis for G-Protein Coupled
Receptors (GPCRs) by Assay Type - cAMP Functional Assays,
Calcium Functional Assays, •-Arrestin Functional Assays,
Radioligand Binding & GTPyS Functional Assays, Internalization
Assays and Other Assay Types - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 III-31

Table 86: China Historic Review for G-Protein Coupled Receptors
(GPCRs) by Assay Type - cAMP Functional Assays, Calcium
Functional Assays, •-Arrestin Functional Assays, Radioligand
Binding & GTPyS Functional Assays, Internalization Assays and
Other Assay Types Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2015 through 2019 III-32

Table 87: China 12-Year Perspective for G-Protein Coupled
Receptors (GPCRs) by Assay Type - Percentage Breakdown of Value
Sales for cAMP Functional Assays, Calcium Functional Assays,
•-Arrestin Functional Assays, Radioligand Binding & GTPyS
Functional Assays, Internalization Assays and Other Assay Types
for the Years 2015, 2020 & 2027 III-33

Table 88: China Current & Future Analysis for G-Protein Coupled
Receptors (GPCRs) by Application - Cancer Research, Metabolic
Research, Inflammation Research, CNS Research, Respiratory
Research, Cardiovascular Research and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-34

Table 89: China Historic Review for G-Protein Coupled Receptors
(GPCRs) by Application - Cancer Research, Metabolic Research,
Inflammation Research, CNS Research, Respiratory Research,
Cardiovascular Research and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05817993/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]   
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

Related Links

www.reportlinker.com